

Serial No. 09/675,323
Filed: September 28, 2000



Applicant(s) : Lardy, et al.
Serial No. : 09/675,323
Filed : September 28, 2000
For : Therapeutic Treatment of Androgen Driven Conditions
Group Art Unit: 1623

AMENDMENT and RESPONSE TO OFFICE ACTION

COMMISSIONER OF PATENTS

P.O. BOX 1450

ARLINGTON, VA 22313-1450

In response to the action the Office mailed on June 6, 2003, enclosed are:

- (X) Amendment and Response to Office Action
- (X) Information Disclosure Statement (Form PTO-1449)
- (X) Return postage prepaid postcard
- (X) Please charge the fee for Submission of Information Disclosure Statement as set forth in 37 CFR 1.17(q) of \$180.00 to **Deposit Account No. 501536**
- (X) Please charge the three-month extension fee of \$475.00 to **Deposit Account No. 501536**. A duplicate of this transmittal is enclosed.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, now or in the future, or credit any overpayment, to **Account No. 501536**. A duplicate copy of this sheet is enclosed.

12/30/2003 NVILLARI 00000001 501536 09675323

| | |
|------------|-----------|
| 01 FC:2253 | 475.00 DA |
| 02 FC:1806 | 180.00 DA |

Serial No. 09/675,323
Filed: September 28, 2000

PATENT
Attorney Docket No. 208.3A
Date: December 3, 2003
Page 2

(X) Please use **Customer No. 26,551** for the correspondence address.

12-3-03
Date

Daryl D Muenchau
Daryl D. Muenchau
Reg. No. 36,616

Hollis-Eden Pharmaceuticals, Inc.
4435 Eastgate Mall, Suite 400
San Diego, CA 92121
(858) 587-9333 (phone)
(858) 558-6470 (fax)